Guotai Haitong: siRNA drug technology upgrades drive breakthroughs in common disease treatment, Chinese companies can achieve differentiated advantages in multiple areas

Guotai Haitong released a research report pointing out that the upgrade of siRNA drug technology is driving the transition from rare diseases to common diseases, especially in the fields of cardiovascular diseases and chronic hepatitis B. With the advancement of the GalNac delivery system, Chinese companies can gain differentiated advantages in technology iteration and drug development. Future breakthroughs may lie in the exploration of targets in new disease areas and innovations in extrahepatic delivery systems. Licensing transactions in this field will continue, and pharmaceutical companies need new products to cope with the patent cliff

Shenwan Hongyuan: Small nucleic acid drugs enter a rapid development stage, domestic companies accelerate to seize the blue ocean

Shenwan Hongyuan released a research report indicating that the small nucleic acid drug market is rapidly developing, with an expected market size of USD 46.7 billion by 2033. Domestic companies are accelerating their layout, focusing on chronic diseases such as cardiovascular diseases and hepatitis B. Small nucleic acid drugs have advantages over traditional drugs, such as shorter development cycles and a wide range of targets, and the market is expected to further expand

Innovative drug concept stocks surged and then fell back, with Mengke Pharmaceutical dropping over 10%, BrightGene, Bio-S falling over 7%, and YKYY, Konruns, EASTON BIOPHARMACEUTICALS, Fushine among those with the largest declines

YKYY's subsidiary YKYY013 injection has received FDA clinical trial approval

YKYY's subsidiary, Beijing YKYY Technology Co., Ltd., has received FDA approval to conduct clinical trials for YKYY013 injection. This drug is used for the treatment of chronic hepatitis B virus infection, utilizing RNA interference technology aimed at inhibiting HBV replication and promoting host immune reconstitution, ultimately achieving functional cure for hepatitis B

YKYY: Independent director Cheng Hua has applied for resignation due to personal reasons

YKYY announced that the board of directors recently received a written resignation letter from independent director Cheng Hua. Cheng Hua applied to resign from her position as an independent director of the company's second board of directors for personal reasons and will no longer hold any position in the company after her resignation. As of the announcement date, she does not hold any shares and has no unfulfilled commitments. The original term of the company's second board of directors is set to expire on June 27, 2025, and the re-election work is currently being prepared. Cheng Hua's resignation will result in the number of independent directors being less than one-third of the board members, and her resignation will take effect after the shareholders' meeting elects a new independent director; she will continue to perform her duties until then